Some cancer treatments raise the risk of heart disease years or even decades later. Radiation to the chest and a group of chemotherapy drugs called anthracyclines are the best documented.
That does not mean the treatment was the wrong choice. It means your heart deserves a place in your long-term follow-up, and that your own risk depends on what you received, how much, and how old you were at the time.
Key takeaways
- Chest radiation and anthracycline chemotherapy can affect the heart long after cancer treatment ends.
- The added risk rises with dose and can keep building for 20 to 30 years or more.
- Ordinary risk factors such as smoking and high blood pressure stack on top of treatment effects.
- Guidelines advise a low threshold for heart evaluation in anyone who had potentially heart-toxic therapy.
- Standard risk calculators do not ask about cancer treatment, so tell every clinician your history.
Why survivors carry added heart risk
Two things overlap. Cancer and heart disease share risk factors, including smoking and obesity. And some treatments affect the heart muscle, the valves or the coronary arteries directly.
The scale is larger than many people expect. An analysis of more than 3.2 million US cancer survivors found that about 11% died of cardiovascular disease, and that their risk of cardiovascular death stayed above that of the general population throughout follow-up.1
An American Heart Association statement on breast cancer makes a related point. For older women, cardiovascular disease poses a greater threat to life than the breast cancer itself.2
Chest radiation
Radiation aimed at the chest can expose the heart, depending on the cancer, its location and the technique used. The effect on the coronary arteries has been measured carefully in breast cancer.
A study of 2,168 women in Sweden and Denmark who had radiotherapy for breast cancer between 1958 and 2001 estimated each woman's heart dose from her treatment chart. The rate of major coronary events rose by 7.4% for each gray of average dose to the heart, with no apparent safe threshold. The increase began within the first five years and continued into the third decade after treatment.3
The same study found that women who already had cardiac risk factors at the time of radiotherapy had larger absolute increases in risk. Treatment and ordinary risk factors add up.
Hodgkin lymphoma shows the long tail. Among 2,524 Dutch survivors treated before age 51, those followed for 35 years or more still had four to six times the expected rate of coronary heart disease or heart failure. Radiation to the center of the chest was linked with more coronary disease, valve disease and heart failure.4
Your own exposure depends on when and how you were treated. Your oncology team can tell you whether your heart was in the radiation field and roughly what dose it received.
Chemotherapy and other cancer drugs
Anthracyclines are widely used in breast cancer, lymphoma, leukemia and sarcoma. Their main heart effect is on the muscle, which can weaken and lead to heart failure.
In the Dutch Hodgkin lymphoma study, chemotherapy containing an anthracycline was linked with about three times the risk of heart failure compared with treatment without one.4
People treated as children carry the risk longest. In the Childhood Cancer Survivor Study, 14,358 five-year survivors were compared with their siblings. Survivors were about six times as likely to report heart failure and five times as likely to report a heart attack, and the number of heart problems kept rising up to 30 years after diagnosis.5
Other cancer drugs can also affect the heart or its risk factors. The details differ by drug, so ask your oncology team which of your treatments are relevant.
| Treatment | Heart problems linked to it | When they tend to appear |
|---|---|---|
| Radiation to the chest | Coronary artery disease, valve disease, heart failure | From a few years to several decades later |
| Anthracycline chemotherapy | Weakened heart muscle and heart failure, valve disease | During treatment or many years later |
| Both together | The effects appear to add up | Long-term follow-up matters most here |
Who is at higher risk
The studies above point to the same handful of factors:
- Higher doses. More radiation to the heart and higher total anthracycline doses mean more risk.
- Younger age at treatment. In the Hodgkin lymphoma study, relative risks were highest in people treated before age 25.
- Combined treatment. The joint effects of chest radiation, anthracyclines and smoking appeared to be additive.
- Existing risk factors. High blood pressure, high cholesterol, diabetes and smoking all count for more, not less, after cancer treatment.
What heart follow-up looks like
The American Society of Clinical Oncology has a guideline on this for survivors of adult cancers. It advises that suspicion for heart disease should be high, and the threshold for a cardiac evaluation low, in any survivor who received potentially heart-toxic therapy. For certain higher-risk survivors, it says routine surveillance with cardiac imaging may be warranted after treatment ends.6
Many hospitals now have cardio-oncology services, where cardiologists work alongside cancer teams. If you had chest radiation or an anthracycline and no one has discussed your heart, it is reasonable to ask your oncologist or primary care doctor whether a referral makes sense.
Three practical steps help whoever looks after you:
- Keep a written treatment summary: drug names, total doses if known, radiation site and dates.
- Mention your cancer history at every heart-related visit. Standard risk calculators are built on age, blood pressure, cholesterol, smoking and diabetes. They do not ask about radiation or chemotherapy, so they can underestimate your risk.
- Report new breathlessness, swelling in the legs, chest discomfort or palpitations promptly.
Your next step
Surveillance of treatment effects, such as heart imaging after an anthracycline, belongs with your oncology or cardiology team. What you can add is a clear view of the ordinary risk factors, because those are the part of your risk that can still change.
Our guide to a heart disease risk assessment explains what a preventive evaluation covers, and the coronary calcium score guide explains one way calcified plaque in the heart arteries is measured. You can also answer the three quick questions in the screener on the Cardio Res-Q program page. Cardio Res-Q is a prevention program. It does not replace your oncologist or a cardiologist, and we share results with your existing doctors.
Are You a Candidate for Cardio Res-Q?
Three quick questions about the risk factors we screen for. Your answers stay between you and the clinic.
Frequently asked questions
How long after cancer treatment can heart problems appear?
It varies widely. After breast radiotherapy, the rise in coronary events began within five years and continued for at least 20 years. In Hodgkin lymphoma survivors, risk was still raised 35 years or more after treatment. This is why follow-up is long term.
Does every cancer survivor need heart testing?
No. Risk depends on which treatments you had, the doses, your age at the time and your other risk factors. Oncology guidance focuses on survivors who received potentially heart-toxic therapy, with imaging surveillance for certain higher-risk groups. Your oncology team can tell you which group you are in.
Can I lower my heart risk after cancer treatment?
You cannot change the treatment you received, but the other risk factors still matter. In the breast radiotherapy study, women with existing cardiac risk factors had the largest absolute increases in risk. Keeping blood pressure, cholesterol, blood sugar and smoking under review with your clinician addresses the part of the risk that is open to change.
Related reading
This article is for general education and is not medical advice. Decisions about testing and medication should be made with your clinician. If you have chest pain or other symptoms of a heart attack, call 911.
